Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Roivant Sciences Ltd.. A complete text table follows the diagram.
Its subsidiary model spreads autoimmune and inflammatory drug development across focused teams, with nine selected programs already at NDA or potentially registrational stages.
Swipe to explore
Program counts and development stages are exact aggregations of the selected pipeline table. The title's 'shots' language is editorial shorthand for indication-level clinical programs. The diagram does not estimate approval probabilities, commercial value or risk-adjusted economics.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Selected clinical pipeline | 1 | 11 | 11 indication-level programs |
| Priovant | 2 | 3 | Brepocitinib across 3 indications |
| Immunovant | 2 | 7 | Anti-FcRn programs across 7 indications |
| Pulmovant | 2 | 1 | Inhaled mosliciguat program |
| NDA filed | 3 | 1 | Brepocitinib in dermatomyositis |
| Registrational or potentially registrational | 3 | 8 | Filing rows marked with an asterisk |
| Phase 2 | 3 | 2 | Cutaneous lupus and PH-ILD |
| From | To | Value |
|---|---|---|
| Selected clinical pipeline | Priovant | 3 |
| Selected clinical pipeline | Immunovant | 7 |
| Selected clinical pipeline | Pulmovant | 1 |
| Priovant | NDA filed | 1 |
| Priovant | Registrational or potentially registrational | 2 |
| Immunovant | Registrational or potentially registrational | 6 |
| Immunovant | Phase 2 | 1 |
| Pulmovant | Phase 2 | 1 |